Esperion Therapeutics’ (ESPR) Buy Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a report released on Wednesday morning, Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock. A number of other brokerages have also recently weighed in on ESPR. Bank of America cut Esperion Therapeutics from […]
More Stories
Oliver Luxxe Assets LLC Buys 4,368 Shares of Leonardo DRS, Inc. (NASDAQ:DRS)
Oliver Luxxe Assets LLC grew its stake in shares of Leonardo DRS, Inc. (NASDAQ:DRS – Free Report) by 5.1% during...
Oliver Luxxe Assets LLC Buys 4,368 Shares of Leonardo DRS, Inc. (NASDAQ:DRS)
Oliver Luxxe Assets LLC grew its stake in shares of Leonardo DRS, Inc. (NASDAQ:DRS – Free Report) by 5.1% during...
Oliver Luxxe Assets LLC Purchases 19,847 Shares of Mueller Industries, Inc. (NYSE:MLI)
Oliver Luxxe Assets LLC grew its position in shares of Mueller Industries, Inc. (NYSE:MLI – Free Report) by 33.5% in...
Oliver Luxxe Assets LLC Purchases 19,847 Shares of Mueller Industries, Inc. (NYSE:MLI)
Oliver Luxxe Assets LLC grew its position in shares of Mueller Industries, Inc. (NYSE:MLI – Free Report) by 33.5% in...
KLA Co. (NASDAQ:KLAC) Shares Purchased by Fortem Financial Group LLC
Fortem Financial Group LLC lifted its holdings in shares of KLA Co. (NASDAQ:KLAC – Free Report) by 2.1% in the...
KLA Co. (NASDAQ:KLAC) Shares Purchased by Fortem Financial Group LLC
Fortem Financial Group LLC lifted its holdings in shares of KLA Co. (NASDAQ:KLAC – Free Report) by 2.1% in the...